In Brief: Chantal Pharmaceuticals
This article was originally published in The Rose Sheet
Executive Summary
Chantal Pharmaceuticals: Twelve of 19 "dissident" stockholders have announced an agreement to work with and support the existing Chantal management team, despite an earlier SEC 13D filing, which said they would seek replacements for several top executive and board members including director and CEO Chantal Burnison, Chantal announced July 1. Shareholders have agreed to vote for new executives and board members at the company's annual meeting July 17. Chantal responded to the 13D by filing suit against the stockholders ("The Rose Sheet" June 16, p. 11)...